Watch More Highlights
Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC, of Cincinnati Cancer Advisors, discusses the phase III DUO-O trial, which evaluates paclitaxel/carboplatin (PC) followed by maintenance bevacizumab (Arm 1); PC plus bevacizumab plus durvalumab followed by maintenance bevacizumab plus durvalumab (Arm 2); and PC plus bevacizumab plus durvalumab followed by maintenance bevacizumab plus durvalumab plus olaparib (Arm 3) in patients with advanced ovarian cancer without a tumor BRCA1/2 mutation in the first-line setting. The primary endpoint is progression-free survival (Abstract LBA5506).